EOLS insider trading
NasdaqGM HealthcareEvolus, Inc.: insider trade history from SEC Form 4 filings.
About Evolus, Inc.
Evolus, Inc., a performance beauty company, delivers products in the cash-pay aesthetic market in the United States, Canada, Europe, and Australia. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults; and Evolysse, a collection of injectable hyaluronic acid gels, which includes various products, such as mid face, nasolabial folds, lips and eyes. The company was incorporated in 2012 and is headquartered in Newport Beach, California.
Company website: www.evolus.com
EOLS insider activity at a glance
FilingIQ tracks 240 insider transactions for EOLS in filings since Feb 13, 2018. The most recent transaction is dated Sep 2, 2026.
Across the full history, 45 open-market purchases
and 100 open-market sales
were filed under transaction codes P and S respectively. Compensatory share awards
(code A) and option exercises (code M) are tracked separately and not counted here.
The average FilingIQ composite score on EOLS insider trades is 50.1/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.
Latest EOLS Form 4 filings
Most recent disclosures. Sign up to filter by score, transaction code, or insider role.
Other Healthcare tickers with recent insider activity
Frequently asked
- How many insider trades does FilingIQ track for EOLS?
- FilingIQ tracks 240 Form 4 insider transactions for EOLS (Evolus, Inc.), covering filings from Feb 13, 2018 onwards. 1 of those are dated within the last 90 days.
- Are EOLS insiders net buyers or net sellers?
- Across the full Form 4 history for EOLS, 45 transactions (19%) were open-market purchases and 100 (42%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
- Where does EOLS insider data come from?
- Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ normalises insider identity across reporting variations and scores discretionary open-market purchases and sales on its multi-factor composite model.
- What sector is EOLS in?
- Evolus, Inc. (EOLS) is classified in the Healthcare sector, specifically Drug Manufacturers - Specialty & Generic, with a current market capitalisation of $314.24M.
Methodology & sources
Every EOLS insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.